Chiltern, a global CRO, is expanding its clinical development services in endocrinology and metabolism and has named Randy Anderson, Ph.D., as senior vice president of scientific affairs.

With nearly 30 years of industry experience, Anderson is an expert in diabetes and other endocrine/metabolism disorders. A board director for JDRF International, he also serves on multiple scientific advisory boards for pharmaceutical companies with endocrine products.

He joins Chiltern after 18 years with another major clinical research organization, where he provided scientific leadership for the endocrinology and metabolism therapeutic area and was a contributor on hundreds of trials and products. In addition to being the therapeutic area leader for endocrinology and metabolism, Anderson will serve as Chiltern’s administrative leader for its other scientific affairs experts across all therapeutic areas.

The endocrinology and metabolism area at Chiltern includes diseases of the endocrine organs and related complications: type 1 diabetes, type 2 diabetes, diabetes complications, obesity, dyslipidaemias, adrenal disorders, thyroid disorders, pituitary disorders, calcium homeostasis disorders, cardiovascular disease prevention, growth disorders, sex androgen dysfunction and other rare metabolic disease indications such as lysosomal storage disorders, Prader-Willi Syndrome and Fabry disease.

“Expanding our clinical development services for endocrinology and metabolism diseases is a direct response to client desire for collaborative partnerships in development planning, design and execution of clinical trials in this complex therapeutic area,” said Dr. Jim Esinhart, Chiltern CEO.